These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 7098029)

  • 1. [Action mechanism and metabolism of 17-spirolactones in the body].
    Miyazaki T
    Nihon Rinsho; 1982; 40(3):652-9. PubMed ID: 7098029
    [No Abstract]   [Full Text] [Related]  

  • 2. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Casals-Stenzel J; Buse M; Wambach G; Losert W
    Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of aldosterone blockers.
    Fanestil DD
    Semin Nephrol; 1988 Sep; 8(3):249-63. PubMed ID: 2849183
    [No Abstract]   [Full Text] [Related]  

  • 4. Extrarenal effects of aldosterone and antimineralocorticoid compounds.
    Moura AM; Angeli M; Worcel M
    Kidney Int Suppl; 1988 Oct; 26():S8-11. PubMed ID: 2848978
    [No Abstract]   [Full Text] [Related]  

  • 5. [Steroid spirolactones--antagonists of mineralocorticoids].
    Linèt O
    Cesk Farm; 1969 Jun; 18(4):218-26. PubMed ID: 4895579
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of RU 28318 on 22Na and 86Rb efflux from arterial smooth muscle].
    Moura AM; Worcel M
    Nephrologie; 1985; 6(3):144. PubMed ID: 4080073
    [No Abstract]   [Full Text] [Related]  

  • 7. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
    Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential antiapoptotic activity of aldosterone antagonists in postinfarction remodeling.
    Biondi-Zoccai GG; Abbate A; Baldi A
    Circulation; 2003 Jul; 108(4):e26. PubMed ID: 12885738
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aldosterone antagonists: new pharmacologic prospects].
    De Jong W; Grima M; Barthelmebs M; Stephan D; Imbs JL
    Therapie; 1998; 53(3):237-43. PubMed ID: 9773123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
    Liang YH; Wang JM; Zhou Y; Jiang XJ; Jiang H; Huang CX
    Life Sci; 2004 Aug; 75(15):1871-8. PubMed ID: 15302230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological mechanism of modern diuretics. Aldosterone antagonists].
    Kinouchi T; Shimizu N
    Nihon Rinsho; 1984 Sep; 42(9):1994-2000. PubMed ID: 6097705
    [No Abstract]   [Full Text] [Related]  

  • 12. [Direct action of mineralocorticoid antagonists on biosynthesis of aldosterone: comparative activities of several new compounds].
    Netchitailo P; Perroteau I; Delarue C; Leboulenger F; Capron MH; Vaudry H
    Can J Physiol Pharmacol; 1983 Jan; 61(1):23-8. PubMed ID: 6301660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro.
    Weindel K; Lewicka S; Vecsei P
    Arzneimittelforschung; 1991 Sep; 41(9):946-9. PubMed ID: 1796922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
    Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 17. Working heart function in diabetes is not improved by spironolactone treatment.
    Verma S; Yuen VG; Badiwala M; Anderson TJ; McNeill JH
    Can J Physiol Pharmacol; 2003 May; 81(5):493-6. PubMed ID: 12774856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro inhibition of aldosterone-stimulated sodium transport by steroidal spirolactones.
    Porter GA
    Mol Pharmacol; 1968 May; 4(3):224-37. PubMed ID: 5661772
    [No Abstract]   [Full Text] [Related]  

  • 19. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone antagonists. 1. Synthesis and activities of 6 beta,7 beta:15 beta,16 beta-dimethylene steroidal spirolactones.
    Nickisch K; Bittler D; Casals-Stenzel J; Laurent H; Nickolson R; Nishino Y; Petzoldt K; Wiechert R
    J Med Chem; 1985 May; 28(5):546-50. PubMed ID: 3989815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.